A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
- Registration Number
- NCT02133911
- Lead Sponsor
- University Medical Centre Ljubljana
- Brief Summary
Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave symptoms of angina in patients with stable coronary disease that is not suitable for surgical or percutaneous revascularization. It has been shown that in patients with stable coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in patients with dilated cardiomyopathy.
- Detailed Description
Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave symptoms of angina in patients with stable coronary disease that is not suitable for surgical or percutaneous revascularization. The main mechanism of action of Ranolazine is the inhibition of late I(Na) thus decreasing the Ca++ load in the cardiomyocites. Consequently oxygen consumption also decreases. It has also been shown that in patients with stable coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in patients with dilated cardiomyopathy.
Primary end-point: To determine wheather Ranolazine improves perfusion of the myocardium in patients with non-ischemic dilated cardiomyopathy.
Secondary end-points: To determine wheather Ranolazine improves patients' NYHA functional class, excercise capacity, LV systolic and diastolic function and weather ranolazine affects supraventricular and ventricular arrhythmia occurance/frequency.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
- established diagnosis of non-ischemic dilated cardiomyopathy
- EF < 35%
- NYHA f.c. II - IV
- Optimal medical management > 6 months
- Age < 75 years and > 18 years
- known hypersensitivity to the medication
- age > 75 years or < 18 years
- EF > 35%
- renal insufficiency (GF < 30)
- liver dysfunction (liver tests > 3x the upper normal limit))
- LQT syndrome
- drugs that affect CYP3A4 metabolism (azoles, macrolides, calcineurin inhibitors etc.)
- dementia
- active hemathological or malignant disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Ranolazine Ranolazine Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
- Primary Outcome Measures
Name Time Method Myocardial perfusion 6 months To determine wheather Ranolazine improves perfusion of the myocardium in patients with non-ischemic dilated cardiomyopathy assesed by myocardial nuclear imaging.
- Secondary Outcome Measures
Name Time Method Excercise capacity 1, 3 and 6 months To determine wheather Ranolazine improves patients' excercise capacity, assesed by 6' walk test
Left ventricular systolic and diastolic function 1, 3 and 6 months To determine wheather Ranolazine improves patients' LV systolic and diastolic function, assesed by LVEF, TDI, LV longitudinal strain and strain rate
Supraventricular and ventricular arrhythmias 6 months To determine wheather Ranolazine affects the occurence of supraventricular and ventricular arrhythmia occurance/frequency using 24 holter monitor.
Trial Locations
- Locations (1)
Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia
🇸🇮Ljubljana, Slovenia